• 1. An Aptamer Bio-barCode (ABC) assay using SPR, RNase H, and probes with RNA and gold-nanorods for anti-cancer drug screening
  Chengbin Yang,Hing Lun Tsang,Pui Man Lau,Ken-Tye Yong,Ho Pui Ho,Siu Kai Kong Analyst, 2017,142, 3579-3587
• 2. Acetylcholinesterase amperometric detection system based on a cobalt(II) tetraphenylporphyrin-modified electrode
  Analyst, 1996,121, 1123-1126
• 3. An automatic determination of thoria in thoria-urania mixtures
  Analyst, 1966,91, 208-210
• 4. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549
• 5. An amphoteric reactivity of a mixed-valent bis(μ-oxo)dimanganese(iii,iv) complex acting as an electrophile and a nucleophile?
  Muniyandi Sankaralingam,So Hyun Jeon,Yong-Min Lee,Mi Sook Seo,Wonwoo Nam Dalton Trans., 2016,45, 376-383

• Solvents and Organic Chemicals Organic Compounds Organoheterocyclic compounds Pyridines and derivatives Methylpyridines

1-Cyclopentyl-1-(6-Methylpyridin-2-yl)Methanamine: A Comprehensive Overview

1-Cyclopentyl-1-(6-methylpyridin-2-yl)methanamine is a compound with the CAS number 1337625-07-6, representing a unique structure that combines a cyclopentyl group with a 6-methylpyridin-2-yl moiety. This compound has garnered attention in the fields of organic chemistry and pharmacology due to its potential applications in drug design and development. Recent studies have highlighted its role in modulating various biological pathways, making it a subject of interest for researchers exploring novel therapeutic agents.

The molecular structure of 1-cyclopentyl-1-(6-methylpyridin-2-yl)methanamine is characterized by a central methanamine group, which serves as a bridge between the cyclopentyl and 6-methylpyridin-2-yl substituents. The cyclopentane ring introduces steric bulk and rigidity, while the 6-methylpyridine group contributes aromaticity and potential hydrogen bonding capabilities. This combination makes the compound versatile in terms of reactivity and bioavailability, as evidenced by recent research into its pharmacokinetic properties.

Recent advancements in computational chemistry have enabled researchers to predict the electronic properties and interaction profiles of 1-cyclopentyl-1-(6-methylpyridin-2-yl)methanamine with high accuracy. For instance, studies utilizing molecular docking simulations have revealed its potential to bind to specific protein targets, such as G-protein coupled receptors (GPCRs), which are critical in various physiological processes. These findings underscore the compound's potential as a lead molecule in drug discovery programs targeting conditions like inflammation, pain, and neurological disorders.

In terms of synthesis, 1-cyclopentyl-1-(6-methylpyridin-2-yl)methanamine can be prepared via a variety of routes, including nucleophilic substitution and coupling reactions. One notable approach involves the reaction of cyclopentylamine with appropriately substituted aryl halides under palladium-catalyzed coupling conditions. This method not only ensures high yields but also allows for fine-tuning of the substituents to optimize pharmacological properties. Recent optimizations in this synthesis pathway have significantly reduced reaction times and improved product purity, making it more amenable for large-scale production.

The pharmacological profile of 1-cyclopentyl-1-(6-methylpyridin-2-yl)methanamine has been extensively studied in preclinical models. Experimental data indicate that it exhibits potent activity against inflammatory cytokines, suggesting its potential utility in treating autoimmune diseases. Additionally, studies on its neuroprotective effects have shown promising results in models of neurodegenerative disorders, highlighting its ability to modulate oxidative stress pathways. These findings are supported by recent publications that emphasize the compound's bioavailability and safety profile when administered at therapeutic doses.

From an industrial perspective, 1-cyclopentyl-1-(6-methylpyridin-2-yli)methanamine is increasingly being recognized as a valuable intermediate in the synthesis of advanced pharmaceuticals. Its structural versatility allows for further functionalization to create derivatives with enhanced potency and selectivity. For example, researchers have explored the addition of hydroxamic acid groups to improve metalloenzyme inhibition or the introduction of fluorinated substituents to enhance metabolic stability.

In conclusion, 1-cyclopentyl-1-(6-methylpyridin-2-yli)methanamine (CAS No: 1337625076) stands out as a compelling candidate for drug development due to its unique structure and diverse biological activities. Ongoing research continues to uncover new insights into its mechanisms of action and therapeutic potential, positioning it as a key player in the field of medicinal chemistry.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)